RecruitingPhase 1Phase 2NCT06590857
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates and/or Chemotherapy (TRACY-1).
Sponsor
RayzeBio, Inc.
Enrollment
124 participants
Start Date
Jul 19, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Subjects must meet all the following criteria for enrollment in the study:
- Eastern Cooperative Oncology Group performance status ≤2.
- Histologically confirmed, ER+, HER2-negative, locally advanced and unresectable or metastatic breast cancer not amenable to treatment with curative intent.
- At least one RECIST v1.1-measurable tumor lesion that is SSTR-PET positive (defined as maximum standard uptake value (SUVmax) higher than liver mean standard uptake value (SUVmean) on SSTR-PET imaging) and at least 80% of RECIST v1.1measurable tumor lesions are SSTR-PET positive
- Sufficient renal function, as evidenced by eGFR ≥60 mL/min/1.73m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
- Adequate hematologic and hepatic function
Exclusion Criteria8
- Subjects who meet any of the following criteria will be excluded from the study:
- Prior radiopharmaceutical therapy, including radioembolization.
- Any toxicities from prior treatments that have not recovered to CTCAE Grade ≤1, except for alopecia.
- Significant cardiovascular disease
- Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, spinal cord compression, or leptomeningeal disease.
- History of hypersensitivity or allergy to 225Ac, 68Ga, 64Cu, octreotate, or any of the excipients of DOTATATE imaging agents.
- Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the study safety or efficacy assessments.
- Pregnancy or lactation.
Interventions
DRUGRYZ101
Ac-225
Locations(31)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06590857
Related Trials
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT066493311 location
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT0699384410 locations
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT059645044 locations
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT0699702921 locations